Lineage Cell Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing allogeneic cell therapies for degenerative diseases and traumatic injuries. It has no commercial products and earns revenue primarily through collaborations, licensing agreements, research funding, milestones and potential royalties. Its lead program is OpRegen, a retinal pigment epithelium cell therapy partnered with Roche and Genentech for geographic atrophy. Other programs address spinal cord injury, hearing loss, photoreceptor dysfunction, corneal disease and Type 1 diabetes. The AlloSCOPE platform supports pluripotent stem cell differentiation and manufacturing across the pipeline. Sources: 0001193125-26-093992#Business; 0001193125-26-338064#Business
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Development and scaling of the proprietary AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering) platform. This includes the AlloSCOPE '5D' application aimed at higher scale production of specialized human cells with reduced manipulation.
Expected impact: Enables large-scale, cost-effective, and consistent production of off-the-shelf cell therapies, enhancing the commercial viability of the entire pipeline.
A cell therapy manufacturing initiative focused on the large-scale production of undifferentiated pluripotent cells. If successful, the technology could be evaluated for the production of islet cells to support a potential treatment for Type 1 Diabetes.
Expected impact: Expands the company's therapeutic reach into endocrine disorders and provides a new high-value candidate for potential strategic partnerships.
Preclinical development of COR1, a corneal endothelial disease cell therapy program launched in early 2026 to address vision loss due to corneal dysfunction.
Expected impact: Broadens the ophthalmic pipeline beyond retinal diseases, leveraging the company's cell transplant expertise.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Jointly advances the preclinical development of Lineage's auditory neuronal cell transplant program, ReSonance (ANP1), for the treatment of hearing loss and auditory neuropathy.
Terms: WDI will contribute up to $12 million in research collaboration costs over a three-year term.
Exclusive worldwide rights granted to Roche/Genentech to develop and commercialize OpRegen (RG6501) for the treatment of ocular disorders, including geographic atrophy secondary to dry AMD.
Terms: Lineage received a $50 million upfront payment and is eligible to receive up to $620 million in additional developmental, regulatory, and commercialization milestone payments, plus tiered double-digit royalties on net sales.